A study using H1975 lung cancer cells resistant to afatinib showed that treatment with HDAC inhibitors sodium valproate or AR42 decreased the expression of several members of the tyrosine kinase receptor family: ERBB1, ERBB2, ERBB3 and ERBB4, and c-MET. This evidence concerns the gene HDAC9 and lung cancer.